Product Description
Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04554914)
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Belgium | Croatia | Czech | European Medicines Agency | Finland | Germany | Greece | Iceland | Ireland | Italy | Lithuania | Poland | Portugal | Slovakia | Sweden
Approved Indications: None
Known Adverse Events: None
Company: Allogene Therapeutics
Company Location: SOUTH SAN FRANCISCO CA 94080
Company CEO: David Chang
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, France, Italy, Spain, United Kingdom, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Allogeneic Stem Cell Transplant|Hematopoietic Stem Cell Transplant|Lymphoproliferative Disorders|Stem Cell Transplant|Transplantation Unspecified
Phase 2: Acquired Immunodeficiency Syndrome|Deficiency Diseases|Epstein-Barr Virus Infections|Leiomyosarcoma|Lymphohistiocytosis, Hemophagocytic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ALLELE study | P3 |
Unknown status |
Transplantation Unspecified |
2032-01-17 |
|
| EBVision | P2 |
Recruiting |
Acquired Immunodeficiency Syndrome|Hematopoietic Stem Cell Transplant|Leiomyosarcoma|Deficiency Diseases|Epstein-Barr Virus Infections|Lymphoproliferative Disorders|Transplantation Unspecified|Allogeneic Stem Cell Transplant |
2027-06-01 |
32% |
| 2020-000177-25 | P2 |
Active, not recruiting |
Lymphohistiocytosis, Hemophagocytic|Leiomyosarcoma |
2024-07-04 |
|
| ALLELE | P3 |
Recruiting |
Hematopoietic Stem Cell Transplant|Lymphoproliferative Disorders|Allogeneic Stem Cell Transplant|Transplantation Unspecified |
2022-06-01 |
54% |